Saturday 17 October 2026
Export LPCN’s income statement to Excel — free account
Lipocine Inc.
LPCN Healthcare Biotechnology
Lipocine Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 82.3% from fiscal 2024. In the quarter to June 2026, revenue fell 69.5%, EPS grew 22.0% and free cash flow fell 60.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.56
0.12
−7.14%
Follow LPCN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 1 | — |
+8 more TTM periods Free account |
| (60.94%) | (54.41%) | (54.28%) | (32.92%) | ||
| (55.89%) | (49.87%) | (48.73%) | (29.78%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(54.51%) | (50.14%) | (66.61%) | (38.78%) | |
Average Days of Receivables |
67.72 | 42.07 | 214.12 | 9.74 | |
Free Cash Flow per Share |
(1.36) | (1.48) | (1.79) | (0.95) | |
Free Cash Flow |
(11.19) | (10.05) | (9.76) | (5.14) | |
| Other line items | |||||
Cash ROIC |
(24.85%) | (21.13%) | (33.19%) | (17.56%) | |
Accounts Receivable Turnover |
7.60 | 9.77 | 2.88 | 41.81 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
649.34% | 513.77% | 434.26% | 161.45% | |
Selling, General and Administrative Expense of Revenue |
251.46% | 192.09% | 190.42% | 84.53% | |
Share Based Compensation of Revenue |
14.64% | 11.83% | 12.27% | 6.68% | |
Operating CF/Net income |
0.94 | 0.88 | 1.01 | 0.94 | |
Depreciation/Fixed assets |
(2.71) | (1.91) | (1.27) | (1.54) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.19 | 0.29 | 0.36 | 0.80 | |
Operating CF per Share |
(1.36) | (1.48) | (1.79) | (0.95) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates